Axsome Therapeutics

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axsome Therapeutics reports robust Q4 performance and eyes global expansion

Axsome Therapeutics had a strong Q4 2022, driven by successful commercialization of Auvelity and Sunosi.
While facing challenges such as legal disputes and payer coverage, the company is well-positioned for growth.
Strategic opportunities in expanding product portfolio and market access present avenues for future success.
Financially stable with a focus on innovation, Axsome is poised for continued growth and market expansion.

Axsome Therapeutics excels in Q1 2023 despite financial hurdles

Axsome Therapeutics demonstrated strong commercial and pipeline progress in Q1 2023, despite financial challenges.
The company's focus on expanding market share and optimizing commercial operations bodes well for future growth.
While facing challenges in sales guidance and NDA filings, Axsome's strong financial position and product performance offer opportunities for sustained success.

Axsome Therapeutics reports robust Q2 sales and expands product portfolio

Axsome Therapeutics demonstrated strong sales performance driven by Auvelity and Sunosi, with a focus on future growth potential.
Despite challenges such as increased costs and a net loss, the company is strategically expanding its product portfolio and market reach.
Opportunities lie in new FDA indications for existing products and the goal to have five marketed products by 2025.

Axsome Therapeutics reports robust Q3 earnings and outlines growth strategies

Axsome Therapeutics delivered strong revenue growth in Q3 2023, driven by Auvelity and Sunosi, showcasing a promising commercial outlook.
The company's pipeline progress and upcoming milestones reflect a commitment to innovation and expansion in the CNS therapeutic space.
While challenges like ongoing losses and strategic resource allocation persist, opportunities in new markets and product diversification offer avenues for future growth.

Axsome Therapeutics reports robust 2023 performance and eyes growth opportunities

Axsome Therapeutics had a strong financial performance in 2023, driven by the success of Auvelity and Sunosi. Despite challenges like increased expenses and net loss, opportunities for growth exist through new indications and expanded payer coverage.

Axsome Therapeutics excels in Q1 2024, poised for growth

Axsome Therapeutics demonstrated exceptional financial growth and pipeline advancements in Q1 2024, particularly in neuroscience programs like AXS-12.
Strong commercial performance of Auvelity and Sunosi, coupled with stable payer coverage and growth strategies, underpin the company's success trajectory.
While facing challenges related to study timelines and cybersecurity, Axsome Therapeutics remains poised to capitalize on upcoming milestones and market opportunities.

Axsome Therapeutics excels in Q2 2024, eyes market expansion

Axsome Therapeutics delivered a strong performance in Q2 2024, driven by revenue growth and progress on key product developments.
While facing challenges in market competition and operational execution, the company remains optimistic about future prospects.
Strategic opportunities in market expansion and product innovation position Axsome well for sustained growth and success in the CNS treatment space.

Axsome Therapeutics excels in Q3 with record revenue and pipeline progress

Axsome Therapeutics delivered a strong performance in Q3 2024, surpassing $100 million in quarterly product revenue and maintaining a solid financial position.
The company's strengths lie in its successful products, robust pipeline, and strategic commercial initiatives, supported by a strong cash reserve.
Challenges include managing expenses, navigating market dynamics, and sustaining commercial momentum, while opportunities exist in product launches and market expansion.
Overall, Axsome's performance reflects a balanced approach to growth, innovation, and market competitiveness, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Adaptimmune Therapeutics

G1 Therapeutics

Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.

Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket

AXS-05 labeling discussions with the FDA imply imminent approval. Next 12-18 months will see Axsome transform into a significant commercial neuroscience biotech.

Axsome: One Step At A Time

NEW YORK , June 30, 2022 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the "Class Period"), of the important July 12, 2022 lead plaintiff deadline. SO WHAT: If you purchased Axsome securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM

Axsome's (AXSM) extension of the review period for AXS-05 NDA and CRL for AXS-07 NDA hurt prospects. However, recent positive updates on AXS-05 are driving positive sentiments.

Axsome (AXSM) Hurt by Regulatory Setbacks: Will It Recover?

DBV Technologies SA Sponsored ADR

Let's consider the risk-reward profile of these companies before jumping on the bandwagon.

2 Biotechs That Recently Soared -- Are They Buys?

Did you lose money on investments in Axsome Therapeutics? If so, please visit Axsome Therapeutics, Inc. Shareholder Class Action Lawsuit or contact  Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.

AXSOME THERAPEUTICS, INC. (NASDAQ: AXSM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Axsome Therapeutics, Inc. (NASDAQ: AXSM)

Axsome (AXSM) receives proposed labeling from the FDA for its under-review depression drug candidate, AXS-05, implying a potential approval soon. Shares surge more than 50%.

Axsome (AXSM) Surges Following FDA Label Proposal for AXS-05

New York, New York--(Newsfile Corp. - June 27, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) alleging that the Company violated federal securities laws.Class Period: December 30, 2019 to April 22, 2022Lead Plaintiff Deadline: July 12, 2022No obligation or cost to you.Learn more about your recoverable losses in AXSM:https://www.kleinstocklaw.com/pslra-1/axsome-therapeutics-inc-loss-submission-form?id=29263&from=5

AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - June 27, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the "Class Period"), of the important July 12, 2022 lead plaintiff deadline.SO WHAT: If you purchased Axsome securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

AXSM INVESTOR NEWS: NATIONALLY RANKED ROSEN LAW FIRM Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM

Novartis

Walgreens

While individuals are fearing another pandemic, could health care stocks be a great addition to your watchlist?

Cheap Stocks To Buy Today? 3 Health Care Stocks For Your Watchlist

The Food and Drug Administration could be nearing a decision on Axsome Therapeutics' depression treatment, and AXSM stock rocketed Monday. The post Axsome Therapeutics Just Took Its Key Moving Averages — Here's Why appeared first on Investor's Business Daily.

Axsome Therapeutics Just Took Its Key Moving Averages — Here's Why

Axsome Therapeutics Inc  (NASDAQ:AXSM) is surging today, after the company said it has received proposed labeling from the Food and Drug Administration (FDA) for AXS-05, its drug candidate to treat major depressive disorder.

Axsome Therapeutics Stock Surges on FDA Update

Axsome announced that it had received proposed labeling from the FDA for the company's AXS-05 product candidate.

Axsome Stock Soars on Proposed FDA Labeling for Depression Drug

Axsome Therapeutics (AXSM) stock is rising higher on Monday following an update from the FDA about product labeling for one of its drugs. The post Axsome Therapeutics (AXSM) Stock Soars on FDA Labeling Proposal appeared first on InvestorPlace.

Axsome Therapeutics (AXSM) Stock Soars on FDA Labeling Proposal

Tesla

A tiny biotech company got great news to start off the week.

Tesla's Up as Stock-Split Investors Wait, But This Tiny Nasdaq Stock Is Riding High Monday

The biotech appears to be close to securing final approval for its major depressive disorder drug.

Why Axsome Therapeutics Stock Is On Fire Today

New York, New York--(Newsfile Corp. - June 27, 2022) - Levi & Korsinsky, LLP notifies investors in Axsome Therapeutics, Inc. (NASDAQ: AXSM) ("Axsome" or the "Company") of a class action securities lawsuit.The lawsuit on behalf of Axsome investors has been commenced in the the United States District Court for the Southern District of New York. Affected investors purchased or otherwise acquired certain Axsome Therapeutics, Inc. securities between December 30, 2019 and April 22, 2022. Follow the link...

Axsome Class Action: Levi & Korsinsky Reminds Axsome Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 12, 2022 - AXSM

New York, New York--(Newsfile Corp. - June 24, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the "Class Period"), of the important July 12, 2022 lead plaintiff deadline.SO WHAT: If you purchased Axsome securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...

ROSEN, A TOP RANKED FIRM, Encourages Axsome Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM

NEW YORK , June 23, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the "Class Period"), of the important July 12, 2022 lead plaintiff deadline. SO WHAT: If you purchased Axsome securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

AXSM LOSS ALERT: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a virtual event on Tuesday, June 28, 2022 at 9:00 AM EDT to provide investors an update on Sunosi® (solriamfetol). Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).

Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event

Jazz Pharmaceuticals

Twist Bioscience Corp

These companies have realistic prospects of achieving tremendous growth.

3 Stocks That Could Double by 2025

New York, New York--(Newsfile Corp. - June 17, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the "Class Period"), of the important July 12, 2022 lead plaintiff deadline.SO WHAT: If you purchased Axsome securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

ROSEN, LEADING INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM

CRISPR Therapeutics

The market hasn't been kind to these two stocks lately.

2 Top Biotech Stocks Ready for Bull Runs

NEW YORK , June 14, 2022 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the "Class Period"), of the important July 12, 2022 lead plaintiff deadline. SO WHAT: If you purchased Axsome securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

AXSM SHAREHOLDER ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AXSM

New York, New York--(Newsfile Corp. - June 13, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 2019 and April 22, 2022, inclusive (the "Class Period"), of the important July 12, 2022 lead plaintiff deadline.SO WHAT: If you purchased Axsome securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

ROSEN, A Leading Law Firm, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM

News for Axsome Therapeutics Stock (AXSM)